This trial as well as others are additionally examining the effects of AZD6738 alone or in combination with PARP inhibitor to treat a number of solid tumors, including ATM deficient gastric cancer (NCT03682289, NCT03462342) [55]. This evidence concerns the gene PARP1 and gastric cancer.